Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-09-22-Speech-3-205"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20100922.20.3-205"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Consumer safety is a matter of vital importance to me, particularly when the consumers involved are also patients who are looking to the drugs they take for a cure, or at least a significant improvement in their health.
That is why I consider the compromise agreement reached on the new pharmacovigilance rules to be significant, as it grants the European Medicines Agency centralised powers in this area, particularly through the creation of a pharmacovigilance database. Broader, better and more integrated access to information can be vital in reducing the severity and frequency of certain adverse effects and in simplifying and speeding up the procedures for suspending sales of drugs flagged as having severe adverse effects or for taking them off the market.
Another point I consider important is the decision to set up an easily accessible web portal where all Europeans can find the information leaflet for any drug in their own language. A patient’s right to safety and information is, in my view, a fundamental right, and I shall therefore pay particular attention to the other proposals in the pharmaceutical package that are yet to be examined in this Chamber."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples